Şunu aradınız:: bicalutamide (İngilizce - Estonca)

bicalutamide
bicalutamide

bicalutamide- teva
bicalutamide- teva

bicalutamide peseri
bicalutamide peseri

events (%) in bicalutamide patients
juhud (%) bikalutamiidravi saanud patsientidel

bicalutamide teva 150 mg filmdragerade tabletter
bicalutamide teva 150 mg filmdragerade tabletter

bicalutamide teva 150 mg, comprimés pelliculés
bicalutamide teva 150 mg Εpικaλυµµένa µe λeptό υµένιο dιsκίa

bicalutamide 150 mg film- coated tablets
150 mg

bicalutamide ingers 150 mg tabletki powlekane
bicalutamide ingers 150 mg tabletki powlekane

bicalutamide 150 pch, filmomhulde tabletten 150 mg
bicalutamide 150 pch, filmomhulde tabletten 150 mg

bicalutamide teva 150 mg compresse rivestite con film
bicalutamide teva 150 mg compresse rivestite con film

international non-proprietary name (inn): bicalutamide
rahvusvaheline mittekaubanduslik nimetus (inn): bikalutamiid

bicalutamide -teva 150 mg plė vele dengtos tabletė s
bicalutamide - teva 150 mg plėvele dengtos tabletės

bicalutamide belongs to the group of anti-androgens.
bikalutamiid kuulub antiandrogeenide rühma.

however, an association with bicalutamide cannot be ruled out.
seost bikalutamiidiga ei saa samas ka välistada.

deaths (%) in deaths (%) in bicalutamide patients placebo patients
surmad (%) platseebopatsientidel

bicalutamide teva 150 mg Ε pικ aλυ µµέν a µe λ eptό υ µένιο dι sκί a
bicalutamide teva 150 mg, comprimés pelliculés

overall summary of the scientific evaluation of bicalutamide 150 mg containing medicinal products
bikalutamiidi 150 mg sisaldavate ravimite teadusliku hinnangu ÜldkokkuvÕte

bicalutamide 150 mg is marketed in the eu following national and mutual recognition application procedures.
bikalutamiidi (150 mg) turustatakse euroopa liidus müügiloa taotlemise siseriiklike ja vastastikuse tunnustamise menetluste tulemusel.

l02bb03 bicalutamide is a non-steroidal anti-androgen without any other endocrine activity.
l02bb03 bikalutamiid on mittesteroidne antiandrogeen, millel puudub muu endokriinne aktiivsus.

overall summary of the scientific evaluation of bicalutamide 150 mg containing medicinal products (see annex i)
150 mg bikalutamiidi sisaldavate ravimite (vt lisa i) teadusliku hindamise ÜldkokkuvÕte